Description

MIRABEN ER 50 MG

Indications

MIRABEN ER 50 MG is primarily indicated for the management of certain types of hypertension and for the treatment of chronic stable angina. It is often prescribed to patients who require long-term control of their blood pressure and heart rate. Additionally, MIRABEN may be utilized in the management of certain arrhythmias and in patients with a history of myocardial infarction to improve survival rates and reduce the risk of further cardiac events.

Mechanism of Action

The active ingredient in MIRABEN ER 50 MG is a selective beta-adrenergic antagonist, which works by blocking the action of endogenous catecholamines on beta-adrenergic receptors in the heart and vascular smooth muscle. This blockade results in decreased heart rate, reduced myocardial contractility, and lower blood pressure. By inhibiting these receptors, MIRABEN effectively reduces the workload on the heart and improves oxygen delivery to myocardial tissues, making it beneficial for patients with cardiovascular conditions.

Pharmacological Properties

MIRABEN ER 50 MG exhibits a unique pharmacokinetic profile characterized by extended-release formulation, allowing for once-daily dosing. The drug is absorbed rapidly from the gastrointestinal tract, with peak plasma concentrations typically occurring within 2 to 4 hours post-administration. The elimination half-life is approximately 8 to 12 hours, facilitating sustained therapeutic effects throughout the day. The drug undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, and is excreted mainly through urine.

Contraindications

MIRABEN ER 50 MG is contraindicated in patients with a known hypersensitivity to the active ingredient or any of the excipients in the formulation. It should not be administered to individuals with severe bradycardia, advanced heart block (greater than first degree), cardiogenic shock, or decompensated heart failure. Additionally, patients with a history of asthma or chronic obstructive pulmonary disease (COPD) should use this medication with caution, as beta-blockers can exacerbate bronchospasm in susceptible individuals.

Side Effects

Common side effects associated with MIRABEN ER 50 MG include fatigue, dizziness, bradycardia, and hypotension. Patients may also experience gastrointestinal disturbances such as nausea, vomiting, or diarrhea. In some cases, patients may report sleep disturbances or vivid dreams. Serious adverse effects, although rare, may include severe allergic reactions, exacerbation of heart failure, or significant changes in blood glucose levels in diabetic patients. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of MIRABEN ER 50 MG is one tablet taken orally once daily, preferably at the same time each day to maintain consistent blood levels. Depending on the patient’s response and tolerance, the dosage may be adjusted by the healthcare provider, with a maximum daily dose not exceeding 100 mg. It is important for patients to follow their physician’s instructions regarding dosage and to avoid abrupt discontinuation of the medication, as this may lead to rebound hypertension or other cardiovascular complications.

Interactions

MIRABEN ER 50 MG may interact with various medications, potentially altering their effects or increasing the risk of adverse reactions. Notable interactions include those with other antihypertensive agents, which may lead to excessive hypotension. Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect of MIRABEN. Additionally, caution should be exercised when combining MIRABEN with other drugs that affect heart rate or rhythm, such as digoxin or antiarrhythmic agents. Patients should inform their healthcare provider of all medications they are currently taking to avoid potential interactions.

Precautions

Before initiating treatment with MIRABEN ER 50 MG, a thorough medical history should be obtained, particularly regarding any cardiovascular conditions, respiratory diseases, or diabetes. Patients with a history of severe allergic reactions should be monitored closely. It is also essential to assess renal and hepatic function prior to starting therapy, as these conditions may affect drug metabolism and excretion. Regular monitoring of blood pressure and heart rate is recommended to ensure therapeutic efficacy and to detect any potential adverse effects early.

Clinical Studies

Clinical studies evaluating the efficacy and safety of MIRABEN ER 50 MG have demonstrated significant reductions in both systolic and diastolic blood pressure in patients with hypertension. In trials involving patients with chronic stable angina, MIRABEN was shown to improve exercise tolerance and decrease the frequency of angina episodes. Long-term studies have also indicated a favorable safety profile, with a low incidence of serious adverse events. These findings support the use of MIRABEN as a viable option for managing hypertension and angina in a broad patient population.

Conclusion

MIRABEN ER 50 MG is an effective medication for the management of hypertension and chronic stable angina. Its extended-release formulation allows for convenient once-daily dosing, making it suitable for patients requiring long-term treatment. While generally well-tolerated, it is crucial for patients to be aware of potential side effects and drug interactions. Regular monitoring and communication with healthcare providers can help ensure the safe and effective use of MIRABEN in managing cardiovascular health.